Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis-Reference-Cited by-同舟云学术

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis

Published:2015-11-13 Issue:11 Volume:5 Page:e008217-e008217
ISSN:2044-6055
Container-title:BMJ Open
language:en
Short-container-title:BMJ Open

Author:

Kunath F.,Borgmann H.,Blu mle A.,Keck B.,Wullich B.,Schmucker C.,Sikic D.,Roelle C.,Schmidt S.,Wahba A.,Meerpohl J. J.

Publisher

BMJ

Subject

General Medicine

Reference81 articles.

1. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer;Tomera;J Urol,2001

2. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer;Trachtenberg;J Urol,2002

3. Possible clinical implication of serum testosterone surge caused by the GnRH antagonist degarelix;Arai;ASCO Meeting Abstr,2014

4. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer;Crawford;J Urol,2011

5. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists;Shore;Prostate Cancer Prostatic Dis,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses;Cancers;2023-12-06

2. Evaluation of Electrocardiographic Changes in Girls Receiving Gonadotropin-Releasing Hormone Analogs for Precocious Puberty;The Journal of Pediatric Research;2023-09-01

3. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer;Annual Review of Pharmacology and Toxicology;2022-01-06

4. Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists;Clinical Obstetrics & Gynecology;2021-10-21

5. Degarelix for treating advanced hormone-sensitive prostate cancer;Cochrane Database of Systematic Reviews;2021-08-05